# Belimumab Assessment of Safety in SLE

> **NCT01705977** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 4019 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** Placebo plus standard therapy
- **BIOLOGICAL:** Belimumab 10 mg/kg plus standard therapy
- **OTHER:** Standard therapy

## Key facts

- **NCT ID:** NCT01705977
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-27
- **Primary completion:** 2018-07-30
- **Final completion:** 2022-08-10
- **Target enrollment:** 4019 (ACTUAL)
- **Last updated:** 2024-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01705977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01705977, "Belimumab Assessment of Safety in SLE". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01705977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*